Lower revenue and segment loss in the pharmaceuticals and food business
First written in FY2016-Q3. 11 of 38 entries say "Worsened", first in FY2018-Q3. Latest entry: 2026-11-10.
No other company in this theme has enough history to compare yet.
- FY2026-H1Continued revenue decline; narrower lossAnnual report
「The Pharmaceuticals and Food segment reported revenue of ¥5,385 million, down 3.8% year on year, and segment profit of ¥389 million, down 8.5%.」
The Pharmaceuticals and Food segment changed from revenue growth and a sharp decline in profit in the same period of the previous year to declines in both revenue and profit in the current interim consolidated accounting period. Meanwhile, the decline in segment profit narrowed from 37.8% to 8.5%. - 2026-05-13WorsenedResults
「The Pharmaceuticals and Food segment reported revenue of ¥5,385 million, down 3.8% year on year, and segment profit of ¥389 million, down 8.5%.」
医薬・食品事業は前年同期比で減収減益となり、前期の増収減益から減収減益へ変化している。 - FY2025WorsenedAnnual report
「The Pharmaceuticals and Food segment reported revenue of ¥11,535 million, up 0.8% year on year, and segment profit of ¥980 million, down 20.4%.」
While the Pharmaceuticals and Food segment maintained revenue growth, segment profit declined 20.4%, changing from revenue decline and profit growth in the previous fiscal year to revenue growth and profit decline. - FY2025-H1WorsenedAnnual report
「The Pharmaceuticals and Food segment reported revenue of ¥5,596 million, up 1.8% year on year, and segment profit of ¥425 million, down 37.8%.」
While the Pharmaceuticals and Food segment maintained revenue growth, segment profit fell 37.8% year on year, changing from the previous interim period's revenue decline and profit growth to revenue growth and a sharp decline in profit. - FY2024Continued revenue decline; wider profit growthAnnual report
「The pharmaceuticals and food business reported net sales of ¥11,443 million, down 4.5% from the previous fiscal year, and segment profit of ¥1,230 million, up 3.8%.」
While revenue in the Pharmaceuticals and Food segment continued to decline, segment profit increased, with the increase widening from 2.4% in the previous fiscal year. - FY2024-Q2Continued revenue decline; wider profit growthAnnual report
「The pharmaceuticals and food business reported net sales of ¥5,498 million, down 1.5% year on year, and segment profit of ¥683 million, up 26.1%.」
While the pharmaceuticals and food business continued to report lower revenue, segment profit increased 26.1% year on year, widening the profit growth rate from 1.9% in the previous quarter. - FY2024-Q1Lower Revenue; Higher ProfitAnnual report
「The pharmaceuticals and food business reported net sales of ¥2,763 million, down 0.9% year on year, and segment profit of ¥415 million, up 1.9%.」
The pharmaceuticals and food business posted lower revenue year on year, while segment profit increased. - FY2023AdvancedAnnual report
「The pharmaceuticals and food business reported net sales of ¥11,985 million, up 5.1% from the previous fiscal year, and segment profit of ¥1,185 million, up 2.4%.」
The pharmaceuticals and food business posted higher revenue and profit compared with the comparable results for the previous fiscal year. - FY2023-Q3AdvancedAnnual report
「The pharmaceuticals and food business reported net sales of ¥8,646 million, up 5.4% year on year, and segment profit of ¥1,003 million, up 8.2%.」
The pharmaceuticals and food business posted higher revenue and profit year on year, shifting from higher revenue and lower profit in the previous quarter to higher revenue and profit. - FY2023-Q2WorsenedAnnual report
「The pharmaceuticals and food business reported net sales of ¥5,579 million, up 2.4% year on year, and segment profit of ¥542 million, down 29.3%.」
The pharmaceuticals and food business maintained higher revenue, while segment profit fell 29.3% year on year, shifting from higher revenue and profit in the previous quarter to higher revenue and lower profit. - FY2023-Q1AdvancedAnnual report
「The pharmaceuticals and food business reported net sales of ¥2,788 million, up 6.1% year on year, and segment profit of ¥407 million, up 11.7%.」
The pharmaceuticals and food business posted higher revenue and profit year on year, with both net sales and segment profit exceeding the same period of the previous year. - FY2022No year-on-year comparison due to the adoption of accounting standardsAnnual report
「The pharmaceuticals and food business reported net sales of ¥11,408 million and segment profit of ¥1,157 million.」
The full-year results for the pharmaceuticals and food business are stated, but no year-on-year comparison is provided. - FY2022-Q3Year-on-year comparison not disclosed due to the adoption of accounting standardsAnnual report
「The pharmaceuticals and food business reported net sales of ¥8,200 million and segment profit of ¥927 million.」
The results for the cumulative third quarter of the current consolidated fiscal year in the pharmaceuticals and food business are stated. Year-on-year percentage changes are not provided because of the adoption of the revenue recognition accounting standard. - FY2022-Q2Year-on-year comparison not disclosed due to the adoption of accounting standardsAnnual report
「The pharmaceuticals and food business reported net sales of ¥5,450 million and segment profit of ¥766 million.」
The results for the cumulative second quarter of the current consolidated fiscal year in the pharmaceuticals and food business are stated. Year-on-year percentage changes are not provided because of the adoption of the revenue recognition accounting standard. - FY2022-Q1Year-on-year comparison not disclosed due to the adoption of accounting standardsAnnual report
「② Pharmaceuticals and food business The pharmaceuticals and food business reported net sales of ¥2,627 million and segment profit of ¥365 million.」
The results for the first quarter of the current fiscal year in the pharmaceuticals and food business are stated. Year-on-year percentage changes are not provided because of the adoption of the revenue recognition accounting standard. - FY2021AdvancedAnnual report
「The pharmaceuticals and food business reported net sales of ¥11,117 million, down 1.4% from the previous fiscal year, and segment profit of ¥1,442 million, up 14.3%.」
Revenue continued to decline, but the segment profit growth rate widened from 7.8% in the third quarter to 14.3% for the full year. - FY2021-Q3Continued revenue decline; wider profit growthAnnual report
「The pharmaceuticals and food business reported net sales of ¥8,075 million, down 1.5% year on year, and segment profit of ¥1,068 million, up 7.8%.」
While the pharmaceuticals and food business continued to report lower revenue, segment profit increased 7.8% year on year. The profit growth rate widened from 0.4% in the previous quarter, while the revenue decline narrowed from 4.3%. - FY2021-Q2Continued lower revenue; narrower profit growthAnnual report
「The pharmaceuticals and food business reported net sales of ¥5,359 million, down 4.3% year on year, and segment profit of ¥691 million, up 0.4%.」
While the pharmaceuticals and food business continued to report lower revenue, segment profit remained higher year on year. However, the profit growth rate narrowed from 26.4% in the previous quarter to 0.4%. - FY2021-Q1Continued revenue decline; wider profit growthAnnual report
「The pharmaceuticals and food business reported net sales of ¥2,775 million, down 3.1% year on year, and segment profit of ¥440 million, up 26.4%.」
While the pharmaceuticals and food business continued to report lower revenue, segment profit increased 26.4% year on year, shifting from lower revenue and lower profit in the previous fiscal year to higher profit. - FY2020WorsenedAnnual report
「The pharmaceuticals and food business reported net sales of ¥11,273 million, down 6.3% from the previous fiscal year, and segment profit of ¥1,261 million, down 3.8%. Drink sales were sluggish, while sales of nutritional supplements remained solid.」
The business shifted from lower full-year revenue and modestly higher profit in the previous fiscal year to lower revenue and lower profit. Drinks were sluggish, while nutritional supplements remained solid. - FY2020-Q3WorsenedAnnual report
「The pharmaceuticals and food business reported net sales of ¥8,202 million, down 8.7% year on year, and segment profit of ¥991 million, down 5.9%.」
The pharmaceuticals and food business shifted from lower revenue and higher profit in the previous quarter to lower revenue and lower profit, with the revenue decline rate also widening to 8.7%. - FY2020-Q2Continued revenue decline, with a shift to profit growthAnnual report
「The pharmaceuticals and food business reported net sales of ¥5,597 million, down 5.5% year on year, and segment profit of ¥688 million, up 1.9%.」
The pharmaceuticals and food business continued to report lower revenue, while shifting from lower revenue and lower profit in the previous quarter to lower revenue and higher profit in the second quarter. - FY2020-Q1WorsenedAnnual report
「The pharmaceuticals and food business reported net sales of ¥2,863 million, down 8.4% year on year, and segment profit of ¥348 million, down 2.2%.」
The pharmaceuticals and food business shifted from higher profit amid continued revenue declines through the previous fiscal year to lower revenue and lower profit in the first quarter. - FY2019WorsenedAnnual report
「The pharmaceuticals and food business reported net sales of ¥12,036 million, down 8.8% from the previous fiscal year, and segment profit of ¥1,312 million, up 0.2%.」
The decline in revenue in the pharmaceuticals and food business widened from 2.1% in the previous fiscal year to 8.8%, while profit continued to increase, although the profit growth rate narrowed to 0.2%. - FY2019-Q3Continued revenue decline; wider profit growthAnnual report
「The pharmaceuticals and food business reported net sales of ¥8,982 million, down 4.1% year on year, and segment profit of ¥1,054 million, up 28.7%. Profit increased due in part to more efficient management of selling, general and administrative expenses.」
Revenue continued to decline, while profit increased through more efficient management of selling, general and administrative expenses and other factors, with the profit growth rate widening from 23.0% in the same period of the previous year to 28.7%. - FY2019-Q2RestatedAnnual report
「The pharmaceuticals and food business reported net sales of ¥5,926 million, down 4.4% year on year, and segment profit of ¥676 million, up 23.0%. Profit increased due in part to more efficient management of selling, general and administrative expenses.」
The pharmaceuticals and food business continued to report lower revenue, while segment profit increased through more efficient management of selling, general and administrative expenses and other factors. - FY2019-Q1RestatedAnnual report
「The pharmaceuticals and food business reported net sales of ¥3,125 million, down 0.8% year on year, and segment profit of ¥355 million, up 48.0%.」
The pharmaceuticals and food business continued to report lower revenue while segment profit increased. - FY2018Continued revenue decline; wider profit growthAnnual report
「The pharmaceuticals and food business reported net sales of ¥13,199 million, down 2.1% from the previous fiscal year, and segment profit of ¥1,309 million, up 75.6%.」
Revenue continued to decline, while segment profit shifted from lower profit through the same period of the previous year to substantial profit growth, resulting in higher full-year profit. - FY2018-Q3WorsenedAnnual report
「The pharmaceuticals and food business reported net sales of ¥9,370 million, down 3.6% year on year, and segment profit of ¥819 million, down 4.0%.」
The pharmaceuticals and food business shifted from continued revenue decline and higher profit through the previous quarter to lower revenue and lower profit in the nine-month period of the current consolidated fiscal year. - FY2018-Q2RestatedAnnual report
「The pharmaceuticals and food business reported net sales of ¥6,202 million, down 1.1% year on year, and segment profit of ¥549 million, up 123.0%.」
The pharmaceuticals and food business continued to post lower revenue while segment profit increased substantially, maintaining a pattern of continued revenue decline and higher profit. - FY2018-Q1Lower sales continued, while profits increasedAnnual report
「The pharmaceuticals and food business reported net sales of ¥3,149 million, down 1.4% year on year, and segment profit of ¥240 million, up 60.1%.」
While the pharmaceuticals and food business continued to report lower revenue, segment profit increased substantially year on year. - FY2017AdvancedAnnual report
「The pharmaceuticals and food business reported net sales of ¥13,488 million, up 1.9% from the previous fiscal year, and segment profit of ¥745 million, up 338.0%.」
The pharmaceuticals and food business posted higher full-year revenue, while segment profit also increased substantially from the previous year. - FY2017-Q3RestatedAnnual report
「Pharmaceutical sales exceeded the previous year, while food sales remained strong. As a result, net sales in the pharmaceuticals and food business were ¥9,719 million, up 7.1% year on year, and segment profit was ¥853 million, compared with a segment loss of ¥66 million in the same period of the previous year.」
Sales of pharmaceuticals and food products exceeded the previous year, and the pharmaceuticals and food business continued to post higher revenue and a return to profitability. - FY2017-Q2Turnaround from declining revenue and losses to rising revenue and profitabilityAnnual report
「Pharmaceutical sales exceeded the previous year, while food sales remained strong. As a result, net sales in the pharmaceuticals and food business were ¥6,273 million, up 7.3% year on year, and segment profit was ¥246 million, compared with a segment loss of ¥121 million in the same period of the previous year.」
Sales of pharmaceuticals and food products exceeded the previous year, and the pharmaceuticals and food business shifted from a segment loss to higher revenue and profitability. - FY2017-Q1Continued revenue decline; return to profitabilityAnnual report
「Pharmaceutical sales fell below the previous year, while food sales remained strong. As a result, net sales in the pharmaceuticals and food business were ¥3,193 million, down 4.8% year on year, and segment profit was ¥150 million, compared with a segment loss of ¥185 million in the same period of the previous year.」
Pharmaceutical revenue continued to decline, while food products performed well, and the segment turned from a loss to a profit compared with the previous year. - FY2016-Q3First statedAnnual report
「Sales and profit fell below the previous year due to the recognition of a ¥559 million loss related to the voluntary recall of medicated throat lozenges. As a result, net sales in the pharmaceuticals and food business were ¥9,077 million, down 4.3% year on year, and the segment posted a loss of ¥66 million, compared with segment profit of ¥676 million in the same period of the previous year.」
This indicates deterioration in the pharmaceuticals and food business, including the impact of the voluntary recall.